[Angio-immunoblastic lymphadenopathy].

N J, Struyf; J A, Verhelst; C G, Convens; W J, Beelaerts; R J, Mathijs; C, Mahler

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 1993

Data sources: Europe PubMed Central

[Angio-immunoblastic lymphadenopathy].

descriptionPublicationkeyboard_double_arrow_right Article 07 Oct 1993 Dutch; Flemish Journal:Nederlands tijdschrift voor geneeskunde, volume 137 (issn: 0028-2162,

Copyright policy )

Authors: N J, Struyf; J A, Verhelst; C G, Convens; W J, Beelaerts; R J, Mathijs; C, Mahler;

pmid: 8366940

[Angio-immunoblastic lymphadenopathy].

- Summary
- Subjects
- Metrics

Abstract

Angioimmunoblastic lymphadenopathy is a rare lymphoproliferative disease with a poor prognosis. We saw a 24-year-old female patient with a fulminant evolution of an angioimmunoblastic lymphadenopathy, possibly a recurrence after a 10 years remission.

Keywords

Adult, Male, Prognosis, Doxorubicin, Vincristine, Immunoblastic Lymphadenopathy, Antineoplastic Combined Chemotherapy Protocols, Humans, Prednisone, Female, Cyclophosphamide

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average